Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Equity Ratio (2016 - 2021)

Historic Equity Ratio for Neurocrine Biosciences (NBIX) over the last 12 years, with Q3 2021 value amounting to 0.67.

  • Neurocrine Biosciences' Equity Ratio rose 2465.22% to 0.67 in Q3 2021 from the same period last year, while for Sep 2021 it was 0.67, marking a year-over-year increase of 2465.22%. This contributed to the annual value of 0.65 for FY2020, which is 3312.61% up from last year.
  • Latest data reveals that Neurocrine Biosciences reported Equity Ratio of 0.67 as of Q3 2021, which was up 2465.22% from 0.65 recorded in Q2 2021.
  • Over the past 5 years, Neurocrine Biosciences' Equity Ratio peaked at 0.85 during Q1 2017, and registered a low of 0.43 during Q1 2019.
  • In the last 5 years, Neurocrine Biosciences' Equity Ratio had a median value of 0.49 in 2019 and averaged 0.53.
  • In the last 5 years, Neurocrine Biosciences' Equity Ratio tumbled by 4893.66% in 2017 and then surged by 3312.61% in 2020.
  • Over the past 5 years, Neurocrine Biosciences' Equity Ratio (Quarter) stood at 0.46 in 2017, then grew by 6.35% to 0.48 in 2018, then rose by 0.74% to 0.49 in 2019, then skyrocketed by 33.13% to 0.65 in 2020, then grew by 2.77% to 0.67 in 2021.
  • Its Equity Ratio stands at 0.67 for Q3 2021, versus 0.65 for Q2 2021 and 0.65 for Q1 2021.